Johanna A Kremer Hovinga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3018108/publications.pdf

Version: 2024-02-01

156 papers	8,340 citations	41344 49 h-index	48315 88 g-index
162 all docs	162 docs citations	162 times ranked	5467 citing authors

#	Article	IF	Citations
1	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346.	27.0	625
2	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 511-522.	27.0	480
3	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	1.4	477
4	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	3.8	362
5	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
6	Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood, 2012, 120, 1157-1164.	1.4	249
7	Thrombotic thrombocytopenic purpura. Nature Reviews Disease Primers, 2017, 3, 17020.	30.5	242
8	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600.	5.2	207
9	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	1.5	193
10	Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood, 2017, 130, 2055-2063.	1.4	191
11	IgG subclass distribution of antiâ€ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2009, 7, 1703-1710.	3.8	170
12	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029.	1.4	161
13	Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2005, 3, 1663-1675.	3.8	159
14	ADAMTSâ€13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of Thrombosis and Haemostasis, 2007, 5, 2284-2290.	3.8	153
15	Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood, 2005, 105, 542-544.	1.4	152
16	Impaired DNase1â€mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2015, 13, 732-742.	3.8	109
17	Recombinant ADAMTS13 normalizes von Willebrand factorâ€cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of Thrombosis and Haemostasis, 2011, 9, 936-944.	3.8	106
18	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103

#	Article	IF	Citations
19	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887.	1.6	99
20	Plasma DNA is elevated in patients with deep vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2013, 1, 341-348.e1.	1.6	99
21	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094.	1.4	99
22	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	3.5	99
23	Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2017, 15, 1448-1452.	3.8	94
24	Hereditary Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 381, 1653-1662.	27.0	93
25	Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. Journal of Thrombosis and Haemostasis, 2006, 4, 1146-1148.	3.8	89
26	Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccineâ€“Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology, 2021, 78, 1314.	9.0	89
27	Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thrombosis and Haemostasis, 2006, 95, 212-220.	3.4	86
28	Postâ€SARSâ€CoVâ€2â€vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. European Journal of Neurology, 2021, 28, 3656-3662.	3.3	84
29	Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Seminars in Hematology, 2004, 41, 75-82.	3.4	79
30	Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica, 2007, 92, 936-943.	3.5	75
31	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847.	4.1	75
32	A common origin of the 4143insA ADAMTS13 mutation. Thrombosis and Haemostasis, 2006, 96, 3-6.	3.4	74
33	Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2006, 4, 2355-2364.	3.8	73
34	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101.	1.6	73
35	Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2007, 5, 866-867.	3.8	72
36	Initial experience from a doubleâ€blind, placeboâ€controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 2012, 87, 430-432.	4.1	71

#	Article	IF	Citations
37	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	3.5	69
38	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178.	1.4	68
39	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532.	1.6	63
40	COVIDâ€19 patients often show highâ€titer nonâ€plateletâ€activating antiâ€PF4/heparin IgG antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1294-1298.	3.8	62
41	Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis, 2002, 161, 261-267.	0.8	61
42	Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood, 2004, 103, 4195-4197.	1.4	61
43	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680.	1.4	61
44	VH1â€69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2009, 7, 421-428.	3.8	59
45	Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2012, 2012, 610-616.	2.5	58
46	Treatment of thrombotic thrombocytopenic purpura. Vox Sanguinis, 2006, 90, 245-254.	1.5	57
47	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541.	3.8	57
48	Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood, 2018, 131, 1360-1371.	1.4	57
49	ADAMTS13 activity in sickle cell disease. American Journal of Hematology, 2006, 81, 492-498.	4.1	54
50	Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica, 2014, 99, 779-787.	3.5	51
51	Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707.	2.5	50
52	High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. Journal of Thrombosis and Haemostasis, 2016, 14, 73-82.	3.8	49
53	Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137.	5.8	48
54	Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica, 2004, 89, 320-4.	3.5	46

#	Article	IF	Citations
55	Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	3.8	45
56	Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica, 2008, 93, 172-177.	3.5	44
57	A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. Journal of Thrombosis and Haemostasis, 2004, 2, 54-57.	3.8	43
58	Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie, 2013, 33, 138-143.	1.9	43
59	Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 618-629.	3.8	41
60	The Oklahoma Thrombotic Thrombocytopenic Purpuraâ€“Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286.	2.2	40
61	The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood, 2014, 124, 3469-3479.	1.4	40
62	Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Seminars in Hematology, 2004, 41, 48-59.	3.4	39
63	Current management of thrombotic thrombocytopenic purpura. Current Opinion in Hematology, 2008, 15, 445-450.	2.5	39
64	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	5.2	39
65	Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARSâ€CoVâ€2 vaccination. European Journal of Neurology, 2022, 29, 339-344.	3.3	38
66	Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 1151-1153.	3.8	37
67	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2021, 326, 332.	7.4	37
68	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188.	1.9	35
69	Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2011, 9, 1285-1291.	3.8	34
70	IN VITRO EVALUATION OF THE EFFICACY AND BIOCOMPATIBILITY OF NEW, SYNTHETIC ABO IMMUNOABSORBENTS. Transplantation, 1995, 60, 425-429.	1.0	32
71	Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. Thrombosis Research, 2015, 135, S30-S33.	1.7	32
72	Thromboembolism in patients with congenital afibrinogenaemia. Thrombosis and Haemostasis, 2016, 116, 722-732.	3.4	32

#	Article	IF	Citations
73	Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood, 2021, 137, 3563-3575.	1.4	31
74	Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Medical Weekly, 2003, 133, 325-32.	1.6	29
75	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243.	1.6	27
76	Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. Journal of Immunology, 2016, 197, 3669-3679.	0.8	25
77	A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Annals of Hematology, 2008, 87, 663-666.	1.8	23
78	The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thrombosis and Haemostasis, 2014, 111, 1180-1183.	3.4	23
79	Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence. Journal of Thrombosis and Haemostasis, 2020, 18, 1598-1617.	3.8	23
80	Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2012, 2012, 610-6.	2.5	21
81	Management of Cerebral Venous Thrombosis Due to Adenoviral <scp>COVID</scp>â€19 Vaccination. Annals of Neurology, 2022, 92, 562-573.	5.3	21
82	Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. International Journal of Hematology, 2016, 103, 283-291.	1.6	20
83	Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%â€20%. American Journal of Hematology, 2017, 92, E644-E646.	4.1	20
84	Acquired thrombotic thrombocytopenic purpura. Hamostaseologie, 2013, 33, 121-130.	1.9	19
85	Beta2-Glycoprotein I: Implications for a Regulatory Role in Thrombotic Thrombocytopenic Purpura.. Blood, 2007, 110, 278-278.	1.4	19
86	Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology, 2022, 98, .	1.1	19
87	The von Willebrand Factor-Cleaving Protease (ADAMTS-13) and the Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP). Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 417-421.	0.3	18
88	Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood, 2022, 139, 2720-2724.	1.4	16
89	Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. Swiss Medical Weekly, 2020, 150, w20422.	1.6	15
90	Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Advances, 2022, 6, 993-997.	5.2	14

#	Article	IF	Citations
91	Relationship between In Vitro Lipopolysaccharide-Induced Cytokine Response in Whole Blood, Angiographic In-Stent Restenosis, and Toll-Like Receptor 4 Gene Polymorphisms. Clinical Chemistry, 2005, 51, 516-521.	3.2	13
92	Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, E22.	4.1	13
93	Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI. Blood, 2016, 127, 2934-2936.	1.4	13
94	Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency?. Thrombosis and Haemostasis, 2005, 94, 1186-1189.	3.4	12
95	Obinutuzumab in two patients suffering from immuneâ€mediated thrombotic thrombocytopenic purpura intolerant to rituximab. American Journal of Hematology, 2019, 94, E259-E261.	4.1	11
96	Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 1141-1147.	1.6	10
97	Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the <scp>ADAMTS</scp>13 gene. European Journal of Haematology, 2014, 92, 168-171.	2.2	10
98	Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. Kidney International Reports, 2017, 2, 1088-1095.	0.8	9
99	Characterization of Five Homozygous ADAMTS13 Mutations in Hereditary Thrombotic Thrombocytopenic Purpura â€“ Towards a Phenotype-Genotype Correlation?. Blood, 2008, 112, 274-274.	1.4	9
100	Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swiss Medical Weekly, 2020, 150, w20210.	1.6	9
101	Soluble thrombomodulin in patients with established atherosclerosis. Journal of Thrombosis and Haemostasis, 2004, 2, 200-201.	3.8	8
102	Novel ADAMTS13 mutations in an obstetric patient with Upshawâ€Schulman syndrome. Journal of Clinical Apheresis, 2013, 28, 311-316.	1.3	8
103	Severe Depression Following Recovery From Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2012, 120, 366-366.	1.4	8
104	Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?. Thrombosis and Haemostasis, 2005, 94, 1186-9.	3.4	8
105	Improving on nature: redesigning ADAMTS13. Blood, 2012, 119, 3654-3655.	1.4	7
106	ADAMTS13 gene variants and function in women with preeclampsia: A population- based nested case-control study from the HUNT Study. Thrombosis Research, 2015, 136, 282-288.	1.7	7
107	Estimation of Nuwiq Â® (simoctocog alfa) activity using oneâ€stage and chromogenic assaysâ€”Results from an international comparative field study. Haemophilia, 2019, 25, 708-717.	2.1	7
108	Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl. Hamostaseologie, 2019, 39, 404-408.	1.9	7

#	Article	IF	Citations
109	Acute pancreatitis and thrombotic thrombocytopenic purpura. European Journal of Medical Research, 2008, 13, 481-2.	2.2	7
110	Designed Ankyrin Repeat Proteins: A New Approach to Mimic Complex Antigens for Diagnostic Purposes?. PLoS ONE, 2013, 8, e60688.	2.5	6
111	Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura. Hamostaseologie, 2014, 34, 244-248.	1.9	6
112	Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. International Journal of Molecular Sciences, 2019, 20, 5963.	4.1	6
113	The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.. Blood, 2007, 110, 277-277.	1.4	6
114	Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation. Thrombosis and Haemostasis, 2011, 106, 381-382.	3.4	5
115	Indications for a protective function of beta2â€glycoprotein <scp>I</scp> in thrombotic thrombocytopenic purpura. British Journal of Haematology, 2012, 159, 94-103.	2.5	5
116	Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland. Hamostaseologie, 2020, 40, S5-S14.	1.9	5
117	Discrepant activity levels of von Willebrand factorâ€“cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. Blood, 2003, 102, 1148-1148.	1.4	4
118	Thrombotic thrombocytopenic purpura. The Hematology Journal, 2004, 5, S6-S11.	1.4	4
119	Hypertension in patients with hereditary thrombotic thrombocytopenic purpura. EJHaem, 2020, 1, 342-343.	1.0	4
120	Acquired hemophilia A and plasma cell neoplasms: aÂcase report and review of theÂliterature. Journal of Medical Case Reports, 2020, 14, 206.	0.8	4
121	A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2010, 116, 726-726.	1.4	4
122	Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS)). Blood, 2016, 128, 135-135.	1.4	4
123	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	2.5	4
124	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789.	1.4	4
125	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	2.7	3
126	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739.	1.4	3

#	Article	IF	Citations
127	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744.	1.4	3
128	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142.	1.4	3
129	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 1067-1067.	1.4	3
130	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 1311-1311.	1.4	3
131	Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature. Frontiers in Medicine, 2022, 9, .	2.6	3
132	A new tool to further explore the role of ADAMTS-13 in health and disease. Journal of Thrombosis and Haemostasis, 2006, 4, 952-954.	3.8	2
133	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373.	1.4	2
134	EHA Endorsement of the Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. HemaSphere, 2021, 5, e647.	2.7	2
135	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. Blood, 2007, 110, 1317-1317.	1.4	2
136	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood, 2019, 134, 2366-2366.	1.4	2
137	Successful liver transplantation in a child with acuteâ€onâ€chronic liver failure and acquired thrombotic thrombocytopenic purpura. Liver Transplantation, 2015, 21, 704-706.	2.4	1
138	Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. , 2017, , 851-871.		1
139	Mortality and Morbidities During Long-Term Follow-up After Recovery From Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2012, 120, 362-362.	1.4	1
140	Blocking Protein S Improves Hemostasis in Hemophilia a and B. Blood, 2016, 128, 79-79.	1.4	1
141	Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Journal of Immunology, 2022, 208, 2497-2507.	0.8	1
142	Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome. Blood Advances, 2019, 3, 2664-2667.	5.2	0
143	SantÃ© psychique lors de maladies chroniques Ã lâ€™exemple de lâ€™hÃ©mophilie. Paediatrica, 2021, 32, .	0.0	0
144	Psychische Gesundheit bei chronischen Erkrankungen am Beispiel der HÃmophilie. Paediatrica, 2021, 32, .	0.1	0

#	Article	IF	Citations
145	Factor V Leiden Is Not a Risk Factor for Thrombotic Microangiopathies without Severe ADAMTS13 Deficiency.. Blood, 2004, 104, 850-850.	1.4	0
146	Absolute and Relative Blood Lymphocyte Subset Counts before and during Treatment of Patients with Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 3953-3953.	1.4	0
147	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. Blood, 2007, 110, 1302-1302.	1.4	0
148	Komplexe GerinnungsstÃ¶rungen. , 2010, , 529-569.		0
149	Circulating Nucleosomes Reflect Disease Activity in Patients with Thrombotic Microangiopathies.. Blood, 2010, 116, 1437-1437.	1.4	0
150	Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature. Blood, 2018, 132, 2496-2496.	1.4	0
151	Description of the First Cases with ADAMTS13 Mutations in Hungary. Blood, 2018, 132, 5003-5003.	1.4	0
152	Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2020, 2020, 82-84.	2.5	0
153	Abstract 51: Age Stratified Risk Of Cerebral Venous Sinus Thrombosis After Sars-Cov-2 Vaccination. Stroke, 2022, 53, .	2.0	0
154	Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2. Hamostaseologie, 2003, 23, 103-8.	1.9	0
155	Progress in Haemostasis. From individual patients to pathophysiological insights. Hamostaseologie, 2017, 37, 9-11.	1.9	0
156	Cerebral Venous Sinus Thrombosis Associated with Vaccine-Induced Thrombotic Thrombocytopeniaâ€"A Narrative Review. Clinical and Translational Neuroscience, 2022, 6, 11.	0.9	0